Clear Cell Ovarian Cancer: Understanding This Rare and Aggressive Subtype

Clear cell ovarian cancer is a rare but distinct form of epithelial ovarian cancer that affects thousands of women worldwide each year. Unlike the more common high-grade serous ovarian cancer, and completely distinct from low-grade serous ovarian cancer (LGSOC), this subtype presents unique challenges in both diagnosis and treatment, making it crucial for patients and their families to understand its distinctive characteristics.

Representing approximately 10 to 12% of all ovarian cancers in North America, clear cell ovarian cancer has earned its name from how the cancer cells appear under a microscope — they look transparent or “clear,” like bubbles filled with fluid. 

What Makes Clear Cell Ovarian Cancer Different?

Clear cell ovarian cancer stands apart from other ovarian cancer types in several important ways. 

While high-grade serous ovarian cancer typically affects older women with a median age of 64 years, clear cell ovarian cancer strikes younger women, with a median age of just 55 years at diagnosis.

Most importantly, clear cell ovarian cancer behaves differently than other ovarian cancers. It tends to present as large, unilateral (affecting one ovary) masses and is more likely to be diagnosed at earlier stages. However, when it does spread to advanced stages, it becomes notoriously difficult to treat due to its resistance to standard chemotherapy for ovarian cancer.

Clear Cell Ovarian Cancer Symptoms: What to Watch For

The symptoms of clear cell ovarian cancer mirror those of other ovarian cancers, but there are some notable differences. Like other ovarian cancer symptoms, clear cell ovarian cancer symptoms can be subtle and easily dismissed as everyday discomfort.

Common clear cell ovarian cancer symptoms include:

• Abdominal bloating or swelling that persists for weeks
• Pelvic or abdominal pain that doesn’t go away
• Difficulty eating or feeling full quickly after small meals
• Changes in urination patterns, including frequency or urgency
• Abnormal vaginal bleeding or changes in menstrual periods
• Fatigue that doesn’t improve with rest
• Back pain that seems unrelated to physical activity

What sets clear cell ovarian cancer apart is its association with blood clotting problems. Women with this type of ovarian cancer have a significantly higher risk of developing deep vein thrombosis (blood clots in the legs) or pulmonary embolism (blood clots in the lungs). In fact, venous thromboembolism occurs 2.5 times more frequently in clear cell ovarian cancer patients compared to those with other ovarian cancer types.

Additionally, clear cell ovarian cancer is more commonly associated with hypercalcemia: elevated calcium levels in the blood that can cause symptoms like nausea, confusion, and kidney problems.

Because clear cell ovarian cancer often presents as a large pelvic mass, many women notice abdominal enlargement or can actually feel a lump in their pelvis. This is different from other ovarian cancers that may remain undetectable until they’ve spread throughout the abdomen.

The Connection Between Endometriosis and Clear Cell Ovarian Cancer

One of the most significant risk factors for developing clear cell ovarian cancer is endometriosis. The relationship between these two conditions is so strong that endometriosis is considered not just a risk factor, but potentially a precursor lesion to clear cell ovarian cancer.

Research shows that women with endometriosis have a two- to three-fold higher risk of developing clear cell ovarian cancer compared to those without the condition. This connection has led scientists to study how benign endometrial tissue outside the uterus can undergo malignant transformation.

Notably, clear cell ovarian cancer is sometimes discovered incidentally during diagnostic laparoscopies performed to confirm endometriosis. Since surgery is the only definitive way to diagnose endometriosis, these procedures occasionally reveal early-stage ovarian cancer that might otherwise have gone undetected. This underscores the importance of thorough surgical evaluation when endometriosis is suspected.

Understanding Clear Cell Ovarian Cancer Prognosis

The clear cell ovarian cancer prognosis varies dramatically depending on the stage at diagnosis. This stark difference between early and advanced disease makes timing of diagnosis absolutely critical.

Important note: Ovarian cancer survival rates have been improving steadily over the years due to advancements in treatment. While these rates are based on large population studies and serve as a general guide, they don’t necessarily reflect individual situations and they do not definitively predict any one person’s journey with ovarian cancer. 

A gynecologic oncologist should be able to answer the patient’s questions and make a more accurate prognosis. They can also provide a more accurate assessment by taking into account personal circumstances and creating a tailored treatment plan. Factors such as the specific type of ovarian cancer, stage at diagnosis, overall health, and response to treatment all play a role in determining a person’s unique prognosis. With the support of a medical team and loved ones, individuals can navigate this challenging time with strength and resilience.

Early-Stage Disease

When caught early, the clear cell ovarian cancer prognosis is relatively favorable. Approximately 57 to 81% of clear cell ovarian cancers are diagnosed at stage I or II, when the cancer is still confined to the ovaries or nearby structures.

The overall five-year survival rate for clear cell ovarian cancer is 66%, but this varies significantly by stage:

• Stage I: 85% five-year survival rate
• Stage II: 71% five-year survival rate

These survival rates show that early detection makes a profound difference in outcomes.

Advanced-Stage Disease

Unfortunately, the clear cell ovarian cancer prognosis becomes much more concerning for advanced-stage disease. When the cancer has spread beyond the pelvis, survival rates drop dramatically:

• Stage III: 35% five-year survival rate
• Stage IV: 16% five-year survival rate

What makes advanced clear cell ovarian cancer particularly challenging is its resistance to standard chemotherapy. While high-grade serous ovarian cancer often responds well to platinum-based chemotherapy, clear cell ovarian cancer shows response rates of only 20 to 50% to these same treatments.

Interestingly, clear cell ovarian cancer has a better prognosis than high-grade serous carcinoma when confined to the pelvis, but a worse prognosis if it reaches advanced stages.

Factors That Influence Prognosis

Several factors can influence an individual’s clear cell ovarian cancer prognosis:

Positive prognostic factors:

• Early stage at diagnosis (most important)
• Complete surgical removal of all visible disease
• Presence of endometriosis
• PIK3CA mutations

Negative prognostic factors:

• Advanced stage at diagnosis
• Positive lymph nodes
• Lymphovascular invasion
• Loss of ARID1A protein expression
• Certain genetic alterations including MET or MDM2 amplification

Diagnosing Clear Cell Ovarian Cancer

Diagnosing clear cell ovarian cancer involves several steps, often beginning when a woman or her doctor notices symptoms or a pelvic mass during examination.

Initial Evaluation

The diagnostic process typically starts with:

• Pelvic examination to check for masses or abnormalities
• Blood tests to measure tumor markers, though clear cell ovarian cancer presents unique challenges in this area. That’s because CA-125 is often less elevated in clear cell ovarian cancer compared to other types, with most patients having levels ≤ 200 U/mL. CA 19-9 (typically associated with pancreatic cancer) may be elevated in some clear cell ovarian cancer patients and can serve as an alternative tumor marker. Napsin A is showing promise as a potential biomarker specifically for clear cell ovarian cancer, with research demonstrating its value in distinguishing this subtype from other ovarian cancers. Alpha-fetoprotein (AFP) levels remain unclear in the research, with some studies suggesting possible elevation while others continue to show CA-125 as the primary marker.
• Imaging studies such as transvaginal ultrasound, CT scans, or MRI

Interestingly, CA-125 levels are typically lower in clear cell ovarian cancer patients, with most having levels ≤ 200 U/mL. This can sometimes make early detection more challenging compared to other ovarian cancer types.

Imaging Characteristics

Clear cell ovarian cancer has distinctive features on imaging studies:

• Large, predominantly cystic masses
• Solid nodules protruding into cystic spaces
• Usually affects only one ovary
• May show signs of hemorrhage or complex fluid

Surgical Diagnosis

The definitive diagnosis requires surgical removal and microscopic examination of tissue. During surgery, doctors look for the characteristic patterns of clear cell ovarian cancer:

• Tubulocystic growth patterns
• Papillary structures
• Solid areas with clear or eosinophilic cells
• Hobnail cells lining tubules and papillae (hobnail cells are abnormal cells with enlarged nuclei that protrude into the cavity, resembling the head of a hobnail nail)

Treatment Options for Clear Cell Ovarian Cancer

Treatment for clear cell ovarian cancer follows many of the same principles as other ovarian cancer treatments, but with some important modifications due to its unique characteristics.

Surgery: The Foundation of Treatment

Surgery remains the cornerstone of clear cell ovarian cancer treatment. The goal is complete debulking surgery to remove all visible disease.

One notable challenge with clear cell ovarian cancer surgery is that these tumors are more likely to present with adhesions and scarring, potentially due to the strong link between clear cell ovarian cancer and endometriosis. This can make the surgical procedure more complex and technically demanding.

For early-stage disease, standard surgery includes:

• Removal of the affected ovary and fallopian tube
• Total hysterectomy and removal of the opposite ovary (in most cases)
• Comprehensive staging including lymph node sampling
• Omentectomy (removal of the fatty tissue covering abdominal organs)
• Peritoneal biopsies

Because clear cell ovarian cancer is aggressive and less responsive to chemotherapy, fertility-sparing surgery is rarely considered, even for very early-stage disease. The standard approach for stage I disease is complete surgical staging followed by adjuvant chemotherapy with paclitaxel, rather than surgery alone.

For advanced disease, the surgery becomes more extensive, potentially involving removal of parts of the bowel, diaphragm, or other organs to achieve complete cytoreduction. The presence of adhesions can make these extensive surgeries even more challenging.

Chemotherapy Challenges

Chemotherapy for ovarian cancer in clear cell types presents unique challenges. The standard combination of carboplatin and paclitaxel, which works well for high-grade serous ovarian cancer, is less effective in clear cell ovarian cancer.

Despite this reduced effectiveness, chemotherapy is still recommended for:

• Most patients with stage I disease and above
• Patients with advanced-stage disease
• Some patients with recurrent disease

The response rates to platinum-based chemotherapy in clear cell ovarian cancer range from 20 to 50%, significantly lower than the 70 to 80% response rates seen in high-grade serous ovarian cancer.

Emerging Targeted Therapies

Given the poor response to traditional chemotherapy, researchers are actively investigating targeted therapies specifically for clear cell ovarian cancer. These include:

Immune checkpoint inhibitors: The drug pembrolizumab has shown promise in clinical trials. Clear cell ovarian cancer may be more susceptible to immunotherapy because of its unique molecular characteristics.

Anti-angiogenic agents: Drugs that target blood vessel formation, such as bevacizumab, are being studied in combination with chemotherapy and immunotherapy.

ARID1A-Targeted Therapies: Since ARID1A mutations are so common in clear cell ovarian cancer, researchers are developing treatments that specifically target tumors with this genetic alteration.

HIF-2α inhibitors: Belzutifan, an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, is currently being studied in a clinical trial at Dana-Farber Cancer Institute. This drug works by targeting the body’s oxygen-sensing mechanisms that allow tumors to survive in low-oxygen environments. Already FDA-approved for clear cell renal cancer, belzutifan represents a promising new approach for clear cell ovarian cancer treatment.

Living with Clear Cell Ovarian Cancer

A diagnosis of clear cell ovarian cancer brings unique challenges that extend beyond medical treatment. Because this cancer type is less responsive to standard chemotherapy, patients and families often face additional emotional and practical concerns.

Managing Treatment Side Effects

Many of the chemotherapy side effects seen with ovarian cancer treatment apply to clear cell ovarian cancer as well. However, because treatment may be less effective, patients might need to undergo more treatment cycles or try different drug combinations.

For patients who undergo extensive surgery, recovery can involve managing ovarian cancer post-surgery and adapting to changes like early menopause if both ovaries are removed.

Support and Resources

Connecting with others who understand the unique challenges of clear cell ovarian cancer can be invaluable. Ovarian cancer support groups provide emotional support and practical advice from others who have walked this path.

Follow-up Care

Clear cell ovarian cancer requires vigilant follow-up care due to its tendency to recur and its resistance to treatment. Regular monitoring typically includes:

• Physical examinations every 2 to 4 months initially
• Blood tests to monitor tumor markers
• Imaging studies as recommended by the medical team
• Genetic counseling if indicated

Taking Action

If you’re experiencing persistent symptoms that could indicate ovarian cancer, don’t wait. Early detection of ovarian cancer remains one of the most important factors in improving outcomes for clear cell ovarian cancer.

For those diagnosed with clear cell ovarian cancer, seeking care from a gynecologic oncologist who has experience with this rare subtype is crucial. These specialists understand the unique challenges that clear cell ovarian cancer presents and can provide the most current treatment options.

Remember that while clear cell ovarian cancer is more challenging to treat than some other ovarian cancer types, many patients do achieve long-term survival, especially when the disease is caught early. With continued research and improved understanding of this disease, the outlook continues to improve.